Tag: imaging AI

SIIM 2026 Video Highlights

Posted on by Brian Casey

The annual meeting of the Society for Imaging Informatics in Medicine is always one of the highlights on the radiology calendar. SIIM 2026 was no exception, once again underscoring the vibrant community driving advances in imaging IT.

From radiology reporting to enterprise image management, SIIM 2026 highlighted the state of the art in imaging IT. We talked to many of radiology IT’s key opinion leaders in Pittsburgh, and we’re pleased to bring the discussions to you in this newsletter.

We hope you enjoy watching our SIIM 2026 video coverage as much as we enjoyed producing it! 

Check out the SIIM 2026 video links below or visit the Shows page on our website, and keep an eye out for our next Imaging Wire newsletter on Thursday.

– Brian Casey, Managing Editor

Top Trends from SIIM 2026

Posted on by Brian Casey

Last week’s SIIM 2026 conference demonstrated once again radiology’s ongoing evolution, from a discipline once known for big iron to one dominated by software. From radiology reporting to the evolving AI platform segment, below are the top seven trends from Pittsburgh. 

  • Reporting Stays Red Hot: Radiology reporting was the top theme from SIIM 2025, and the segment got even hotter with Microsoft’s decision to sunset its PowerScribe 360 radiology reporting software, which has drawn a host of new competitors into the segment. At SIIM 2026, a common theme was enterprise imaging companies adding reporting modules to their solutions.  
  • AI Adoption Moving Slowly But Surely: Adoption of radiology AI has been frustratingly slow, but it’s moving inexorably toward broader clinical use. At SIIM 2026, some 68% of the radiology-oriented papers focused on AI in some way, especially the new generation of foundation and vision language models that are enabling targeted AI algorithms to be developed more quickly than ever.
  • AI Governance Gets Real: Growing adoption of AI algorithms is creating a new issue: How to manage all this new technology. AI governance therefore was a major issue at SIIM 2026 as healthcare providers debated the legal and ethical necessity to better manage AI adoption, deployment, and utilization.
  • Other ‘Ologies Get into the Act: Radiology likes to think of SIIM as its own conference, but it also encompasses other ‘ologies that are moving into digital image management, like pathology and ophthalmology. At SIIM 2026, several imaging IT vendors showed integration with data from these disciplines, giving healthcare institutions a single source for their healthcare data management.
  • The Rise of All-in-One Vendors: A growing number of imaging IT vendors are rolling out solutions that combine image viewer, worklist, and reporting into a single platform, simplifying purchasing, deployment, and maintenance for radiology customers. Many of these firms seem to be getting traction with potential buyers, indicating the all-in-one concept could be one whose time has come.
  • Agentic AI Takes Shape: Agentic AI is a growing trend in radiology as algorithm developers build solutions to take on mundane tasks and free up radiologists to focus on their primary task: interpreting images. But the question is, will agentic AI work in the real world, or simply pile more technology on clinicians?
  • What Next for AI Platforms? Bayer’s withdrawal from the AI platform market by pulling its support for Blackford in 2025 raised many questions about the platform model that persisted at SIIM 2026. AI platforms seem to be evolving to add additional services like AI monitoring and governance.

The Takeaway

SIIM may not be radiology’s largest show, but for those in the imaging IT space it may be the most valuable one outside of RSNA. SIIM 2026 proved that point, with the top trends from Pittsburgh illustrating the discipline’s direction at the midpoint of the radiology year. For our overview of the top trends at SIIM 2026, check out our YouTube channel or the Shows tab on our webpage.

AI Reduces Mammography Workload

Posted on by Brian Casey

Using AI to triage low-risk breast screening exams that don’t need extra review could remove more than three-quarters of mammography cases from radiologists’ workload and allow them to spend more time on high-risk cases. That’s according to a new study in Radiology: Artificial Intelligence that confirms other recent studies. 

Much of recent mammography AI research has focused on its ability to triage low-risk cases to avoid additional radiologist review – saving precious personnel resources.

  • This is particularly valuable in Europe, which uses a double-reading paradigm in which two radiologists review all mammography cases (the U.S. employs single readers but tends to screen women annually rather than every two years). 

The new study comes from France, which employs a slightly different paradigm from the rest of Europe. Double reading is conducted only for lower-risk BI-RADS 1 and 2 cases, while BI-RADS 3-5 go directly to diagnostic workup. 

  • As such, double reading occurs with cases that have low cancer prevalence, which can make it more difficult for radiologists to detect cancers that don’t occur very often.

But what if you offloaded low-risk double reading to AI? 

  • In the new paper, researchers tried that with Therapixel’s MammoScreen AI algorithm, which was employed retrospectively to analyze mammograms from 42.4k women acquired from 2015 to 2019.

AI results were compared to standard radiologist double reading, with the following findings…

  • AI classified 77% of cases as low-risk, meaning these could be safely triaged from the double-reading paradigm.
  • AI missed only one cancer in the low-risk group, a rate the researchers characterized as “small but measurable.” 
  • Eleven cancers were found in the group AI classified as non-low-risk, which would have undergone double reading anyway in the AI triage paradigm.
  • Rates of interval cancer (cancer that occurs between screening rounds) were 5X higher in the cases AI classified as non-low-risk compared to low-risk (2.16 vs. 0.47 cancers per 1k exams). 

Using AI to classify and remove low-risk cases from double reading could therefore save significant resources from the French mammography screening program, with a “small but non-zero risk” of missed cancers.

The Takeaway
The new results track with findings from other recent studies that apply AI to mammography screening, particularly in Europe. While the French reading paradigm is unique, it’s instructive to see that AI maintains its ability to reduce radiologist workload across different types of breast cancer screening programs.

AI’s ROI Paradox

Posted on by Brian Casey

As radiology AI slowly moves from pilot projects to widespread clinical adoption, a new survey reveals a paradox: The technology is popular with radiologists, but few imaging facilities using AI have collected hard data showing its return on investment.

AI’s slow clinical adoption has frustrated both clinicians and algorithm developers alike, but the technology is gaining steam.

  • Despite growing clinical evidence, research on AI’s financial value and ROI has been slower in coming. 

To remedy that situation, AI governance startup Croviz.ai conducted a study of 445 radiology AI users on the economics and evaluation of AI. The full report is available here.

  • Survey respondents came from 12 different countries and included a variety of professional roles, including vendor executives, radiologists, and IT and informatics personnel.

Croviz founders Ayman Talkani and AadilMehdi Sanchawala found that while radiology AI power users loved the technology – and some refused to work without it – few had determined a positive financial return from it. Findings included…

  • 95% of sites already using AI had renewed at least one contract with an AI vendor in the last 12 months.
  • But only 30% had quantified a positive financial ROI from AI.
  • 54% cited better quality of life for radiologists as their main reason for renewing an AI contract.

So if AI’s value hasn’t been demonstrated, why are radiology sites renewing AI contracts?

  • The number one reason cited by 54% of those renewing contracts was because their radiologists felt AI improved their quality of life – the only outcome measure leadership could quickly measure with qualitative user feedback.
  • Lower on the scale was reduced turnaround time (18%), more scans per reader (10%), reduced downstream patient costs (10%), and better diagnostic accuracy (8%). 
  • Just 6% paid attention to hard metrics like staff retention rates.

What’s the best way out of the AI ROI paradox? The Croviz researchers recommended more frequent and transparent AI governance.

  • Survey respondents who monitored AI performance more closely – such as more often than once per quarter – exhibited more trust in AI.

The Takeaway

The new survey offers an intriguing look at AI adoption and the question of ROI for the technology. It suggests that – much like another digital technology, PACS – AI adoption is being driven more by its popularity among radiologists than hard ROI considerations.

Doctors Adopt ‘Shadow AI’ for Efficiency Gains

Posted on by Brian Casey

Doctors under pressure to work more efficiently are looking for help from “shadow AI” – artificial intelligence applications adopted outside a formal hospital approval process. A new survey of U.S. healthcare personnel found that many administrators have encountered unauthorized AI tools in their organizations, including some used for direct patient care. 

U.S. healthcare providers are struggling under rising patient volumes in the midst of an ongoing workforce shortage, a situation that’s leading to burnout among clinicians. 

  • AI is often touted as a possible solution by enabling providers to do more with less, but the jury is still out on whether this works in the real world. 

The new survey was conducted by Wolters Kluwer Health to assess usage of what the report described as “shadow AI,” or AI that’s adopted without proper hospital authorization processes. 

  • Shadow AI introduces risk to data, security, and privacy, and providers should better understand the need for an enterprise approach to AI with appropriate controls.

It’s worth noting that the report’s use of the term “authorization” applies primarily to an institution’s internal approval and governance processes for AI rather than formal FDA regulatory authorization. 

  • AI algorithms that aren’t used for direct patient care don’t require FDA authorization, as the agency pointed out in a guidance just a few weeks ago. 

Researchers surveyed 518 health professionals, finding…

  • 41% were aware of colleagues using unauthorized AI tools.
  • 17% said they had personally used an unauthorized tool.
  • 10% said they had used an unauthorized AI tool for direct patient care.

While the report’s recommendation for stronger AI governance is valid, there could be a competitive subtext to the findings. Wolters Kluwer offers healthcare clinical decision support solutions, and the company is currently locked in a fierce battle with OpenEvidence for dominance in the CDS space.

  • OpenEvidence’s CDS solution is wildly popular with clinicians, many of whom install and consult with the software on their own, outside an enterprise-level governance – exactly the kind of “unauthorized” model the new report criticizes.

The Takeaway

The Wolters Kluwer report could be shedding light on a concerning new trend, or it could represent an effort by an established player to shut out a competitive threat. Either way, its warning on the need for appropriate enterprise-level AI governance should not be ignored.

Canon Celebrates 50 Years of CT Innovation: Redefining Healthcare with Meaningful AI

Posted on by Partner Content

This year marks a historic milestone for Canon – five decades of pioneering CT innovation that has transformed the landscape of healthcare. From introducing industry-first technologies to setting new standards in diagnostic imaging, Canon continues to lead the way in delivering solutions that matter.

Canon’s legacy is built on breakthroughs such as its three-time award-winning wide-area CT systems, deep learning reconstruction that brings 1K resolution to CT imaging, and automation improving workflow. 

  • These innovations have consistently elevated diagnostic confidence, patient safety, and operational efficiency.

In today’s world, AI is everywhere – but Canon’s AI is Meaningful AI. It’s not about AI for the sake of technology; it’s about creating real-world impact on patient care. 

  • Canon’s portfolio of scanner-integrated AI applications is designed to enhance image quality, streamline workflows, and improve consistency – ultimately delivering better care, better experience, and better efficiency for patients and providers alike.

Canon is redefining CT by making AI a core component across its portfolio. Key innovations include…

  • AI-Assisted Scanner Workflow Automation. Canon’s INSTINX platform introduces intuitive, intelligent, and integrated AI technologies that enable autonomous CT operations. By simplifying complex workflows, INSTINX helps technologists focus on patient care while improving throughput and reducing variability.
  • AI-Assisted Post-Processing. Canon’s Automation Platform offers a zero-click, AI-driven solution that accelerates image post-processing. By delivering fast, actionable insights, this platform ensures time-critical results reach care teams when they need them most.
  • AI-Assisted Reconstruction. Advanced algorithms such as AiCE DLR and PIQE DLR leverage deep learning to reveal critical diagnostic information – contrast and resolution – while optimizing dose efficiency. These tools empower clinicians to make confident diagnoses and reduce the need for additional downstream studies. Additionally, CLEARMotion, a DCNN-based algorithm, compensates for patient motion, reducing blur and delivering high-quality results even in challenging cases.

The Takeaway 

As Canon celebrates 50 years of CT innovation, its commitment remains clear: harnessing AI to make imaging smarter, faster, and more meaningful. With these advancements, Canon is not just shaping the future of CT – it’s setting a new benchmark for patient-centered care.

FDA AI Approvals Surge Past 1k for Radiology

Posted on by Brian Casey

The number of AI-enabled medical devices granted FDA marketing authorization for radiology surged past the 1k mark in the latest update from the agency. The numbers show that radiology’s share of authorizations remains stable at just over three-quarters of total approvals.

The FDA regularly releases the list in what’s become a closely watched barometer of both total approvals as well as which medical specialties are most active in AI.

  • Radiology has historically garnered the lion’s share of approvals – perhaps no surprise given the discipline’s early adoption of both digital image management and AI – with the first authorization granted in 1998 (for ImageChecker mammography CAD from R2 Technology/Hologic). 

The new list tracks authorizations through the end of September 2025, and indicates the agency has…

  • Authorized 1,356 AI-enabled devices since it started tracking, up 8.5% since its last report.
  • Approved 1,039 AI-enabled radiology devices, with imaging accounting for 77% of total medical authorizations since 1998.
  • Radiology secured 75% of total authorizations from June to September (83/110), compared to 78% from January to May 2025, 73% for all of 2024, and 80% for 2023. 
  • GE HealthCare retains the top spot as the company with the most radiology AI authorizations, at 115 (including recent acquisitions Bay Labs, BK Medical, Caption Health, MIM Software, icometrix, and Spectronic Medical).
  • Next is Siemens Healthineers at 86 (including Varian), then Philips at 48 (including DiA Analysis and TomTec), Canon at 41 (including Vital Images and Olea), United Imaging at 38, and Aidoc at 30. 

As always, it’s worth noting that the FDA’s list includes not only standalone software applications, but also imaging equipment that might have AI applications embedded into it, such as a mobile X-ray system with AI algorithms for detecting emergent conditions. 

  • Also, the agency noted that it is exploring ways to identify and tag AI-based devices that use foundation models and large language models. The FDA has yet to approve an LLM-based medical device.

The Takeaway

The new numbers indicate that radiology’s dominance of medical AI continues. But they also show that the FDA has returned to a regular twice-yearly cadence of updating its list of AI-enabled medical devices after a break of nearly a year – news that’s welcome to AI developers.

RSNA 2025 Video Highlights

Posted on by Brian Casey

RSNA 2025 is a wrap, and this year’s meeting offers an intriguing look at the forces that are shaping radiology – especially AI and imaging informatics.

It’s no secret that AI has come to dominate recent RSNA conferences, with its promise of fundamentally reshaping how radiologists do their jobs.

  • The hope is that by making radiologists more efficient, AI will help radiologists manage rising imaging volumes with a workforce that’s been largely stagnant.

But that dream has been a long time in coming, and the AI sector is being forced to make adjustments as it waits for broader clinical adoption. Many of these trends were on display at RSNA 2025, including…

  • Industry consolidation as AI developers make acquisitions to build out integrated suites of AI algorithms.
  • New questions about the commercial viability of the AI platform model given Bayer’s step back from Blackford.
  • The rise of AI network alliances as alternatives to the integrated suite or platform approaches.
  • Building excitement over the performance of foundation and vision language models for clinical tasks.
  • Renewed attention on radiology reporting as perhaps the primary use case where AI can truly help radiologists work more efficiently. 

Our video interviews from RSNA 2025 explore many of these topics and more, giving you an as-it-happened look at news from McCormick Place.

The Takeaway

We hope you enjoy watching our coverage as much as we enjoyed producing it! Check out the links below, on our YouTube page, or visit the Shows page on our website.

RP Acquires Vision AI Firm Cognita Imaging

Posted on by Brian Casey

Radiology Partners ramped up its investment in AI by acquiring Cognita Imaging, a startup that’s developed AI vision language models for analyzing CT and X-ray images and drafting initial radiology reports. RP executives see the acquisition as going beyond traditional point-source AI models and toward a future where AI automates much of the traditional image interpretation process.

The $80M acquisition expands on an equity stake RP already had in Cognita, which had been operating in stealth mode since its spin-off from Stanford University’s Center for Artificial Intelligence in Medicine and Imaging lab.

  • Cognita was formed by a team led by CEO Louis Blankemeier, PhD, to commercialize Stanford research on vision language models, a type of generative AI that’s far more versatile than the traditional point-source models being commercialized to analyze medical images.

Instead, Cognita’s technology is able to analyze text as well as CT or X-ray images and produce first drafts of radiology reports that just need a radiologist’s review and signature to be complete.

  • Extremely positive clinical tests with Cognita’s VLM models spurred RP to acquire the rest of the company it didn’t already own, said Rich Whitney, chairman and CEO of Radiology Partners. 

Cognita’s technology powers Mosaic Drafting, RP’s new application for helping radiologists draft reports that operates under the company’s recently launched Mosaic Clinical Technologies branding. Early clinical testing has found that Mosaic Drafting…

  • Increases radiologist detection rates by 52%.
  • Results in a fourfold decline in radiologist errors.
  • Reduces radiologist reading times by up to 76%.

RP plans to deploy Mosaic Drafting through Mosaic Clinical Technologies, which the company launched in July as the technological foundation for a massive rollout of AI across its physician practices. 

  • Mosaic Chief Medical AI Officer Nina Kottler, MD, said Mosaic Drafting is currently being used within Radiology Partners under IRB approval, but the company will pursue an FDA authorization – most likely under a de novo pathway – that probably will come sometime in 2026.

In a broader sense, RP sees Mosaic Drafting and other VLM tools as key to the growing mismatch between rising imaging volume and stagnant radiologist supply – a mismatch that can only be solved through greater automation. 

  • And as the largest private radiology organization in the U.S., Radiology Partners has the organizational heft to make VLMs work on a wide scale.

The Takeaway 

RP’s acquisition of Cognita is a major development in putting vision language models on the fast track to real-world clinical use. Unlike point-source AI, VLMs could hold the key to really solving radiology’s volume overload dilemma.

AI in Radiology: Old Problems, New Tech

Posted on by Partner Content

By Mo Abdolell, CEO, Densitas

Radiology has seen this movie before. Big promises (efficiency, accuracy, burnout relief). Big anxieties (ROI, workflow chaos, pressure to “keep up”). The question isn’t whether AI is powerful. It’s whether we’ve learned how to deploy new technology without repeating the pain of PACS migrations and the EHR era.

The Myth of the Perfect Rollout. Health technology assessment (HTA) sounds great in theory – rigorous, comprehensive, evidence-first. In practice, few organizations have the time, talent, or budget to execute it at scale. 

  • Remember EHRs: adoption happened because policy and money forced it, not because the playbook was tidy. Healthcare’s default pattern is to adopt, then evolve – messy, market-driven, and iterative. Waiting for perfect plans is how you get left behind.

Are AI’s Problems really new?

  • Black box déjà vu. Radiology has long trusted complex, opaque systems (reconstruction algorithms, vendor-specific pipelines). What mattered – and still matters – is validated performance and dependable outputs, not full internal transparency.
  • Model drift ≈ old friends. We’ve always recalibrated clinical tools as populations and scanners change. Monitoring and revalidation are known problems, not alien ones.

What’s Different This Time? Unlike the top-down EHR mandate, AI is largely market-driven. That gives providers agency. 

  • AI solutions must save time, improve outcomes, or avoid costs – not just publish a ROC curve. They must show operational value inside the native radiology workflow.

Fortunately, there are ways to adopt AI and then evolve your processes to make it work…

  • Workflow or bust. Demand in-viewer evidence objects, one-click report insertion, and EHR write-back. If AI adds steps, it subtracts value.
  • Start narrow, scale deliberately. Pick high-volume, high-friction tasks. Prove value in weeks, not years. Expand only when the operational signal is undeniable.
  • Measure what matters. Track operational metrics like seconds saved and coverage (e.g. eligible cases processed before dictation), reliability (e.g. results present before finalization, fail-open behavior), and user friction like context-switching rate and time-to-evidence.
  • Monitor. Stand up organization and site-level performance checks. Treat AI like equipment – scheduled, observed, and maintained.
  • Invest in long-term value. Favor standards, vendor-agnostic interoperability, clear telemetry, and transparent pricing.

The Takeaway

AI’s success in radiology won’t be defined by elegance of algorithms but by pragmatism of deployment. This will be an evolution – hands-on, incremental, sometimes messy. The difference now is that radiology can drive. Make the technology serve the service line – not the other way around.

Target the toughest workflows. Adapt and evolve with Densitas Breast Imaging AI Suite.

Get every issue of The Imaging Wire, delivered right to your inbox.